Enhancement of iron chelation therapy

Details Enhancement of iron chelation therapy Enhancement of iron chelation therapy

2007-01-09

2007-01-09

Wax, Robert A. (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S400000

Reexamination Certificate

active

10389424

ABSTRACT:
The present invention provides methods of enhancing the rate of iron release from ferritin. By increasing the amount of iron available for chelation, the invention also provides methods of treating conditions associated with iron overload. The invention also provides in one embodiment agents which are useful for treating iron overload.

REFERENCES:
patent: 4528196 (1985-07-01), Pitt
patent: 5013718 (1991-05-01), Adamson et al.
patent: 5430058 (1995-07-01), Shanzer et al.
patent: 5837677 (1998-11-01), Horwitz
patent: 5922761 (1999-07-01), Lai
patent: 6133322 (2000-10-01), Rustin et al.
patent: 6391852 (2002-05-01), Feder et al.
patent: 6509380 (2003-01-01), Walker, Jr.
patent: 2001/0033860 (2001-10-01), Gwathmey
patent: 2001/0039295 (2001-11-01), Bergeron, Jr.
patent: 2003/0104491 (2003-06-01), Cabantchik
Cragg et al. Blood 92(2): 632-638 (1998). “The Iron Chelator L1 Potentiates Oxidative DNA Damage in Iron-Loaded Liver Cells”.
Jones et al. J Biol Inorg Chem 7: 357-362 (2002). “Formation of a linear [3Fe-4S] cluster in a seven-iron ferredoxin triggered by polypeptide unfolding”.
Calleja et al. Ann N Y Acad Sci 850: 469-470 (1998). “Survival and morbidity in transfusion-dependent thalassemic patients on subcutaneous desferrioxamine chelation”.
Ha et al. J Biol Inorg Chem 4: 243-256 (1999). “Crystal structure of bullfrog M ferritin at 2.8 A resolution: analysis of subunit interactions and the binuclear metal center”.
Kontoghiorghes et al. J Clin Pathol 40: 404-408 (1987). “Iron chelation studies using desferrioxamine and the potential oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats”.
Crichton, R. Inorganic Biochemistry of Iron Metabolism: From Molecular Mechanisms to Clinical Consequences Copyright 2001. Chapter 6, Intracellular Iron Storage and Biomineralization.
Ashley-Koch, A., et al., “Sickle Hemoglobin (Hb S) Allele and Sickle Cell Disease: A HuGE Review,”American Journal of Epidemiology, vol. 151, No. 9, pp. 839-845 May 1, 2000.
Hadley, Kevin, et al., “Effects of Dietary Iron on Ferritin Expression and Tissue Iron in Mouse Models for β-thalassemia, and Sickle Cell Trait,”Itinerary for The American Society of Hematology 44thAnnual Meeting, 1 page, <http://www.abstracts-on-line.com/abstracts/hemphiladelphia02/aol.asp>.
Hagar, Ward, et al., “A Molecular Basis for Resistance to Liver Damage from Transfusional Iron Overload In Sickle Cell Disease,”Itinerary for The American Society of Hematology 44thAnnual Meeting, Dec. 9, 2002, 1 page, <http://www.abstracts-on-line.com/abstracts/hemphiladelphia02/aol.asp>.
Harmatz, Paul, et al., “Organ Injury in Chronically Transfused Patients with β Thalassemia or Sickle Cell Disease,”Itinerary for The American Society of Hematology 44thAnnual Meeting, Dec. 7, 2002, 1 page, <http://www.abstracts-on-line.com/abstracts/hemphiladelphia02/aol.asp>.
Murray-Kol, Laura E., et al., “Women with low iron stores absorb iron from soybeans,”American Journal of Clinical Nutrition, 77, pp. 180-184, (2003).
Olivleri, N.F., et al., “Iron chlating therapy and treatment of thalassemia”,Blood, vol. 89, No. 3, pp. 739-761 (1997).
Oliveiri, N.F., et al., “Long-Term Safety and Effectiveness of Iron-Chelation Therapy with Daferiprone for Thalassemia Major”,N. Engl. J. Med, vol. 339, No. 7, pp. 339:417-423 (1998).
Richardson D.R., et al., “Development of Iron Chelators to Treat Iron Overload Disease and Their Use as Experimental Tools to Probe Intracellular Iron Metabolism,”Am. J. Hematol. 58:299-305 (1998).
Takagi, Hidenori, et al., “Localized Unfolding at the Junction of Three Ferritin Subunits,”The Journal of Biological Chemistry, vol. 273, No. 30, May 8, 1998, pp. 18685-18688.
Theil, Elizabeth C. et al., “Ferritin,”Handbook of Metallioproteins, pp. 771-781 (2001).
Trikha, Jaishree, et al., “High Resolution Crystal Structures of Amphibian Red-Cell L Ferritin: Potential Roles for Structural Plasticity and Solvetion in Function,”Journal of Molecular Biology, 248, pp. 949-967 (1995).
Xiaofeng Liu, et al., “Opening protein pores with chaotropes enhances Fe reduction and chelation of Fe from the ferritin biomineral,” Proceedings of the National Academy of Sciences, Apr. 1, 2003, pp. 3653-3658.
Weili, Jin, et al., “‘Opening’ the Ferritin Pore for Iron Release by Mutation of Conserved Amino Acids at Interhelix and Loop Sites,”Biochemistry., vol. 40, No. 25, pp. 7525-7532 (2001).
Search report from PCT/US03/08212.

Affiliated with

Also associated with

Rating

Enhancement of iron chelation therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Enhancement of iron chelation therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhancement of iron chelation therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3721003